WO2006094627A2 - Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases - Google Patents
Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases Download PDFInfo
- Publication number
- WO2006094627A2 WO2006094627A2 PCT/EP2006/001575 EP2006001575W WO2006094627A2 WO 2006094627 A2 WO2006094627 A2 WO 2006094627A2 EP 2006001575 W EP2006001575 W EP 2006001575W WO 2006094627 A2 WO2006094627 A2 WO 2006094627A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- tetrahydro
- naphthalenyl
- urea
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to the use of hydroxy-tetrahydro-naphthalenylurea derivatives which are described in WO- 03/095420 as an active ingredient of pharmaceutical preparations for the treatment of diseases associated with VRl activity in new indications.
- the hydroxy-tetrahydro- naphthalenylurea derivatives of the present invention are used for the prophylaxis and treatment of diseases associated with VRl activity, in particular for the treatment of respiratory diseases or disorders such as the common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous irritants such as tobacco smoke, smog, high levels of atmospheric SO 2 and noxious gases in the workplace, and airways hyperreactivity, milk product intolerance, Loffier's pneumonia, emphysema, cystic
- Vanilloid compounds are characterized by the presence of a vanillyl group or a functionally equivalent group.
- Examples of several vanilloid compounds or vanilloid receptor modulators are vanillin (4-hydroxy-3-methoxy-benzaldehyde), guaiacol (2-methoxy-phenol), zingerone (4-/4- hydroxy-3-methoxyphenyl/-2-butanon), eugenol(2-methoxy4-/2-propenyl/phenol), and capsaicin (8-methy-N-vanillyl-6-noneneamide).
- capsaicin the main pungent ingredient in "hot” chili peppers, is a specific neurotoxin that desensitizes C-fiber afferent neurons. Capsaicin interacts with vanilloid receptors
- VRl which are predominantly expressed in cell bodies of dorsal root ganglia (DRG) or nerve endings of afferent sensory fibers including C-fiber nerve endings [Tominaga M, Caterina MJ,
- VRl can therefore be viewed as a molecular integrator of chemical and physical stimuli that elicit neuronal signals in a pathological conditions or diseases.
- This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives which are described in WO 03/095420, and which are expressly incorporated as part of the description of this invention, for the treatment of respiratory diseases or disorders such as the common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous irritants such as tobacco smoke, smog, high levels of atmospheric SO 2 and noxious gases in the workplace, and airways hyperreactivity, milk product intolerance, Loffler's pneumonia, emphysema, cystic fibrosis, bronchiectasis, pulmonary fibrosis, pneumoconiosis, collagen vascular disease, granulomatous disease, laryngitis, pharyngitis, pneumonia, ple
- Special selected compounds of WO 03/095420 which are named for this invention for the treatment of respiratory diseases or disorders such as the common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous irritants such as tobacco smoke, smog, high levels of atmospheric SO 2 and noxious gases in the workplace, and airways hyperreactivity, milk product intolerance, Loffler's pneumonia, emphysema, cystic fibrosis, bronchiectasis, pulmonary fibrosis, pneumoconiosis, collagen vascular disease, granulomatous disease, laryngitis, pharyngitis, pneumonia, pleuritis, persistent asthma and chronic asthmatic bronchitis are compounds of formula (I), its tautomeric or stereoisomer ⁇ form,
- Y represents a direct bond
- E 4 and R 2 independently represent hydrogen, chloro, bromo, ⁇ fhioro, cyclopentyl- amino, trifluoromethyl, or trifluoromethoxy;
- R , R and R each represent hydrogen
- Z 1 and Z 2 each represent hydrogen.
- said hydroxy-tetrahydro-naphthalenylurea derivative of the formula (I) is selected from the group consisting of:
- the invention relates to the preparation of medicaments of hydroxy-tetrahydro- naphthalenylurea derivatives which are described in WO 03/095420 for the treatment of respiratory diseases or disorders such as the common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous irritants such as tobacco smoke, smog, high levels of atmospheric SO 2 and noxious gases in the workplace, and airways hyperreactivity, milk product intolerance, Loffier's pneumonia, emphysema, cystic fibrosis, bronchiectasis, pulmonary fibrosis, pneumoconiosis, collagen vascular disease, granulomatous disease, laryngitis, pharyngitis, pneumonia, pleuritis, persistent asthma and chronic asthmatic
- the invention relates to the preparation of medicaments of compounds of formula (I), its tautomeric or stereoisomeric form, or a salt thereof for the treatment of respiratory diseases or disorders such as the common cold, cough, sneeze, bronchitis including acute and chronic bronchitis, bronchiolitis, rhinitis, allergic rhinitis, vasomotor rhinitis, mucositis, sinusitis, allergy, disorders associated with exogenous irritants such as tobacco smoke, smog, high levels of atmospheric SO 2 and noxious gases in the workplace, and airways hyperreactivity, milk product intolerance, Loffler's pneumonia, emphysema, cystic fibrosis, bronchiectasis, pulmonary fibrosis, pneumoconiosis, collagen vascular disease, granulomatous disease, laryngitis, pharyngitis, pneumonia, pleuritis, persistent asthma and chronic asthmatic bronchitis.
- hydroxy-tetrahydro-naphthalenylurea derivatives which are described in WO 03/095420 are used for the treatment of allergic rhinitis.
- the compounds of formula (I), its tautomeric or stereoisomeric form, or a salt thereof are used for the treatment of allergic rhinitis.
- the compounds of WO 03/095420 including the compounds of the formula (I) of the present invention can be ⁇ -but not limited to be, prepared by the methods described in WO 03/095420.
- Typical salts of the compound shown by the formula (I) include salts prepared by reaction of the compounds of the present invention with a mineral or organic acid, or an organic or inorganic base. Such salts are known as acid addition and base addition salts, respectively.
- Acids to form acid addition salts include inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid and the like, and organic acids, such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p- bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid and the like
- organic acids such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p- bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- Base addition salts include those derived from inorganic bases, such as, without limitation, ammonium hydroxide, alkaline metal hydroxide, alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, and organic bases, such as, without limitation, ethanolamine, triethylamine, tris(hydroxymethyl)aminomethane, and the like.
- inorganic bases include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
- the compound of the present invention or a salt thereof may form hydrates and/or other solvates.
- the use of those hydrates, and solvates are included in the scope of the present invention.
- the compound of the present invention may be administered in oral forms, such as, without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions. They may also be administered in parenteral forms, such as, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, and the like forms, well-known to those of ordinary skill in the pharmaceutical arts.
- the compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal delivery systems well-known to those of ordinary skilled in the art, or periungual or buccal or via inhalation.
- the dosage regimen with the use of the compounds of the present invention is selected by one of ordinary skill in the arts, in view of a variety of factors, including, without limitation, age, weight, sex, and medical-condition of the recipient, the severity of the condition to be. treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed, the particular compound and salt thereof employed.
- the compounds of the present invention are preferably formulated prior to administration together with one or more pharmaceutically-acceptable excipients.
- Excipients are inert substances such as, without limitation carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
- the active ingredient may be combined with an oral, and non-toxic, pharmaceutically-acceptable carrier, such as, without limitation, lactose, starch, sucrose, glucose, sodium carbonate, mannitol, sorbitol, calcium carbonate, calcium phosphate, calcium sulfate, methyl cellulose, and the like; together with, optionally, disintegrating agents, such as, without limitation, maize, starch, methyl cellulose, agar bentonite, xanthan gum, alginic acid, and the like; and optionally, binding agents, for example, without limitation, gelatin, natural sugars, beta- lactose, corn sweeteners, natural and synthetic gums, acacia, tragacanth, sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like; and, optionally, lubricating agents, for example, without limitation, magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate,
- the carrier may be a finely divided solid which is in admixture with the finely divided active ingredient.
- the active ingredient may be mixed with a carrier having binding properties in suitable proportions and compacted in the shape and size desired to produce tablets.
- the powders and tablets preferably contain from about 1 to about 99 weight percent of the active ingredient which is the novel composition of the present invention.
- Suitable solid carriers are magnesium carboxymethyl cellulose, low melting waxes, lactose, and cocoa butter.
- Sterile liquid formulations include suspensions, emulsions, syrups and elixirs.
- the active ingredient can be dissolved or suspended in a pharmaceutically acceptable carriers, such as sterile water, sterile organic solvent, or a mixture of both sterile water and sterile organic solvent.
- the active ingredient can also be dissolved in a suitable organic solvent, for example, aqueous propylene glycol.
- a suitable organic solvent for example, aqueous propylene glycol.
- Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
- compositions of this invention may be administered by nasal drops, by nasal aerosols, or as an inhaled powder.
- Suitable nasal spray formulations of inventive compositions can be readily prepared according to techniques well known in the art of pharmaceutical formulation. For example, the preparation of solutions or emulsions are described by Achari et al., U.S. Pat. No. 6, 436,950 (supra), J. G. Nair [Chapt. 39, Solutions, Emulsions, Suspensions and Extracts, pg. 721-752J] and aerosols by J. Sciarra and C. J. Sicarra [Chapt. 50, "Aerosols", pg. 963 to 979] in the standard text: "Remington, the science and practice of pharmacy," Alfonso R. Gennaro, Chairman of the editorial board and editor. 20th ed. Baltimore, Md. Lippincott Williams & Wilkins, 2000.
- compositions the active ingredient may be prepared as gels, liposomal dispersions, suspensions or emulsions in saline, employing benzyl alcohol, benzalkonium chloride or other suitable preservatives, absorption promoters such as cyclodextrins to enhance bioavailability and bioadhesives for prolonged contact, and/or other solubilizing or dispersing agents known in the art.
- a composition for administration to the intranasal surfaces is particularly contemplated that comprises a solution of the active ingredient dissolved or dispersed in a pharmaceutically acceptable diluent (carrier).
- the solvent or wetting agent may be propylene glycol (1,2- propanediol) and a variety of aqueous carriers can be used, e.g. buffered water, 0.9 percent saline, buffered aqueous-ethanol solutions and the like.
- aqueous carriers e.g. buffered water, 0.9 percent saline, buffered aqueous-ethanol solutions and the like.
- These compositions can be sterilized by conventional, well-known sterilization techniques, or can be sterile filtered.
- the resulting solutions can be packaged for use as is or mixed as an adjuvant to another medication.
- compositions can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, and the like.
- auxiliary substances such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, and the like.
- intranasal administration is to administer the active ingredient in powder form; by itself or admixed to an inert carrier such as calcium carbonate or lactose.
- an inert carrier such as calcium carbonate or lactose.
- Methods for preparing spray dried powder with a hydrophilic excipient, e.g. povidone, lactose, and delivering it using dry powder nasal inhalers, have been described by Gordon et al. (U.S. Pat. No. 6,365,190) and are incorporated herein by reference.
- the advantage of a powder method for delivery is that it may have a more prolonged action when administered in dry powder versus in soluble forms, as the nose has robust clearance mechanisms.
- the powder may be prepared in micronized form, by re- crystallization, by granulation, by drying, or by milling to a specified particle size and thus to have a high surface area for interaction with cold receptors.
- Methods for preparing powders are well- known to the art and have been reviewed by R. E. O'Connor and J. B. Schwartz (Powders, Chapt. 37, pg. 681-699) in the standard text: "Remington, the science and practice of pharmacy," Alfonso R 5 , Gennaro, Chairman of the editorial board and editor. 20th ed. Baltimore, Md. Lippincott Williams & “ Wilkms, 2000. To quote from this Chapter (pg. 688):
- the formulation may be in unit dosage form, which is a physically discrete unit containing a unit dose, suitable for administration in human or other mammals.
- a unit dosage form can be a capsule or tablets, or a number of capsules or tablets.
- a "unit dose" is a predetermined quantity of the active compound of the present invention, calculated to produce the desired therapeutic effect, in association with one or more excipients.
- the quantity of active ingredient in a unit dose may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved.
- Typical oral dosages of the present invention when used for the indicated effects, will range from about O.Olmg /kg/day to about 100 mg/kg/day, preferably from 0.1 mg/kg/day to 30 mg/kg/day, and most preferably from about 0.5 mg/kg/day to about 10 mg/kg/day.
- parenteral administration it has generally proven advantageous to administer quantities of about 0.001 to lOOmg /kg/day, preferably from 0.01 mg/kg/day to 1 mg/kg/day.
- the compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. Where delivery is via transdermal forms, of course, administration is continuous.
- the compounds of the present invention were prepared as described in WO 03/095420.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008500067A JP2008532956A (en) | 2005-03-05 | 2006-02-22 | Use of hydroxytetrahydro-naphthalene derivatives |
CA002599778A CA2599778A1 (en) | 2005-03-05 | 2006-02-22 | Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases |
EP06707142A EP1893189A2 (en) | 2005-03-05 | 2006-02-22 | Use of hydroxy tetrahydro-naphthalene derivatives for the treatment of respiratory diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05004878 | 2005-03-05 | ||
EP05004878.4 | 2005-03-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006094627A2 true WO2006094627A2 (en) | 2006-09-14 |
WO2006094627A3 WO2006094627A3 (en) | 2006-12-07 |
Family
ID=36930668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/001575 WO2006094627A2 (en) | 2005-03-05 | 2006-02-22 | Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1893189A2 (en) |
JP (1) | JP2008532956A (en) |
CA (1) | CA2599778A1 (en) |
WO (1) | WO2006094627A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008079683A2 (en) | 2006-12-20 | 2008-07-03 | Abbott Laboratories | N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605623B1 (en) * | 1998-12-18 | 2003-08-12 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
WO2003095420A1 (en) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Hydroxy tetrahydro-naphthalenylurea derivatives |
WO2004052845A1 (en) * | 2002-12-09 | 2004-06-24 | Bayer Healthcare Ag | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
WO2004089877A1 (en) * | 2003-04-14 | 2004-10-21 | Astrazeneca Ab | New hydroxynaphthyl amides |
WO2004099177A1 (en) * | 2003-05-09 | 2004-11-18 | Merck Sharp & Dohme Limited | Substituted-1-phthalazinamines as vr-1 antagonists |
EP1493438A1 (en) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
-
2006
- 2006-02-22 JP JP2008500067A patent/JP2008532956A/en active Pending
- 2006-02-22 CA CA002599778A patent/CA2599778A1/en not_active Abandoned
- 2006-02-22 EP EP06707142A patent/EP1893189A2/en not_active Withdrawn
- 2006-02-22 WO PCT/EP2006/001575 patent/WO2006094627A2/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605623B1 (en) * | 1998-12-18 | 2003-08-12 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
WO2003095420A1 (en) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Hydroxy tetrahydro-naphthalenylurea derivatives |
WO2004052845A1 (en) * | 2002-12-09 | 2004-06-24 | Bayer Healthcare Ag | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
WO2004089877A1 (en) * | 2003-04-14 | 2004-10-21 | Astrazeneca Ab | New hydroxynaphthyl amides |
WO2004099177A1 (en) * | 2003-05-09 | 2004-11-18 | Merck Sharp & Dohme Limited | Substituted-1-phthalazinamines as vr-1 antagonists |
EP1493438A1 (en) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008079683A2 (en) | 2006-12-20 | 2008-07-03 | Abbott Laboratories | N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain |
WO2008079683A3 (en) * | 2006-12-20 | 2008-08-28 | Abbott Lab | N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain |
US8030504B2 (en) | 2006-12-20 | 2011-10-04 | Abbott Laboratories | Antagonists of the TRPV1 receptor and uses thereof |
EP2450346A1 (en) * | 2006-12-20 | 2012-05-09 | Abbott Laboratories | Antagonists of the TRPV1 receptor and uses thereof |
US8350083B2 (en) | 2006-12-20 | 2013-01-08 | Abbvie Inc. | Antagonists of the TRPV1 receptor and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1893189A2 (en) | 2008-03-05 |
JP2008532956A (en) | 2008-08-21 |
CA2599778A1 (en) | 2006-09-14 |
WO2006094627A3 (en) | 2006-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9108900B2 (en) | Method of treating diseases that respond to therapy by dopamine or dopamine agonists | |
JP2002502432A (en) | Compositions and methods for reducing respiratory depression and the side effects of mu opioid compounds | |
JP2008534480A (en) | Glycopyronium salts and their therapeutic use | |
WO2012166909A1 (en) | Compositions and methods for treating breathing control disorders or diseases | |
CN102803285A (en) | Pharmaceutical composition comprising a steroidal[3,2-c]pyrazole derivative and a second pharmaceutically active compound | |
EP0401903A2 (en) | The use of vanilloids for the treatment of respiratory diseases or disorders | |
US20240197770A1 (en) | Compositions and methods for treating elastic fiber breakdown | |
JPH09506622A (en) | 6- (2-imidazolinylamino) quinoxaline compounds useful as α-2-adrenoceptor agonists | |
JP2005533013A (en) | Beta agonist compounds containing a nitric oxide donor group and a reactive oxygen species scavenging group, and use of the compounds in the treatment of respiratory disorders | |
JPH09507219A (en) | 7- (2-Imidazolinylamino) quinoline compounds useful as α-2-adrenoceptor agonists | |
CA2839350A1 (en) | The use of serotonin receptor agonists for treatment of movement disorders | |
TW201442711A (en) | Novel methods | |
US20110124613A1 (en) | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | |
KR20010032009A (en) | Use of mirtazapine for treating sllep apneas | |
WO2006094627A2 (en) | Use of hydroxy tetrahydro-naphtalene derivates for the treatment of respiratory diseases | |
WO2018201192A1 (en) | Compounds for the treatment of respiratory diseases | |
WO2017129061A1 (en) | Application of substituted cinnamamide derivatives in preparation of anti-anxiety medications | |
JP2006504768A (en) | Quaternary ammonium compounds | |
WO2007024183A1 (en) | A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma | |
KR20020072576A (en) | Remedies or Preventives for Pulmonary Insufficiency Containing Diaminotrifluoromethylpyridine Derivatives | |
CN109694376B (en) | Beta-beta2Receptor agonist compounds and their use in the treatment of asthma | |
RU2798874C1 (en) | Compositions for the prevention or treatment of chronic obstructive pulmonary disease (copd) | |
AU2019235887A1 (en) | 3",5"-dialkoxybenzoyl-3'-amino-3'-deoxyadenosine-5'-triphosphates and pharmaceutical uses thereof | |
ZA200408993B (en) | Hydroxy tetrahydro naphthalenylurea derivatives | |
CN114599367A (en) | Composition for preventing or treating Chronic Obstructive Pulmonary Disease (COPD) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006707142 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2599778 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008500067 Country of ref document: JP |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06707142 Country of ref document: EP Kind code of ref document: A2 |
|
WWP | Wipo information: published in national office |
Ref document number: 2006707142 Country of ref document: EP |